FDA Places Hold on Novavax’s COVID-Flu Vaccine IND After Adverse Event
The FDA has placed a hold on Novavax’s Investigational New Drug application for its COVID-19-influenza combination and stand-alone influenza vaccines following a report of an adverse event in a participant from the completed combination trial.